Semaglutide offers broad benefits for diabetes, weight loss, and cardiovascular health but carries risks including pancreatitis and anesthetic complications.
Double-edged swordSemaglutide offers significant metabolic and cardiovascular benefits but carries notable risks
What the researchers found
Semaglutide provides multi-system benefits (glycemic control, weight loss, cardiovascular protection, potential neuroprotection) but carries risks including pancreatitis and anesthetic complications.
Why it matters
With millions now taking semaglutide, both patients and providers need a balanced understanding of its risk-benefit profile.
The numbers in context
Reviews oral and SC semaglutide. Covers glycemic control, weight loss, cardiovascular risk reduction, potential for Alzheimer disease and PCOS. Risks: pancreatitis, aspiration, AKI, gallbladder, NAION, diabetic retinopathy.
How the study worked
Comprehensive narrative review of clinical evidence on semaglutide's mechanisms, benefits, and adverse effects.
Who was studied
Adults with T2D, obesity, and potential neurological indications
What this study cannot tell us
Narrative review — does not systematically weight evidence quality. Some potential benefits (Alzheimer's, PCOS) are still early-stage.
How to read the evidence
Narrative review synthesizing diverse clinical evidence — useful overview but evidence quality varies by indication.
When this study was published
Published in 2025, capturing current understanding of semaglutide's evolving therapeutic profile.
The bigger picture
As semaglutide use expands beyond diabetes into obesity, neurodegeneration, and reproductive health, understanding its full safety profile becomes increasingly critical.
Questions still open
- How should anesthesiologists manage patients on semaglutide before surgery?
- Do the benefits of long-term semaglutide use outweigh cumulative risks?
Common questions
What are the main risks of semaglutide?
Can semaglutide help with conditions beyond diabetes?
Read the original research
Semaglutide: Double-edged Sword with Risks and Benefits.
Archives of internal medicine research, 8(1), 1-13
Citation
Pillarisetti, Lekha; Agrawal, Devendra K. (2025). Semaglutide: Double-edged Sword with Risks and Benefits.. Archives of internal medicine research, 8(1), 1-13. https://doi.org/10.26502/aimr.0189